New drug combo aims to tame rare kidney disease
NCT ID NCT06676579
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding avacopan (a pill that blocks inflammation) to low-dose steroids can help people with crescentic IgA nephropathy, a severe kidney condition. Sixteen adults with high-risk features will be randomly assigned to receive either avacopan plus low-dose steroids or standard high-dose steroids. The main goal is to see if protein in the urine drops significantly after 12 months, which would suggest less kidney damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Avacopan (a drug that blocks a protein called C5a receptor, taken as a pill)
What this could lead to
If it works, this could offer a new treatment option for people with a severe form of IgA nephropathy, potentially reducing kidney damage and delaying or avoiding dialysis or transplant.
What could go wrong
This is a very small, early-phase trial with only 16 people, so results may not apply to everyone. The drug may not work better than standard steroids, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224, United States
Contact
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact